Jeffrey Nornhold - Myovant Sciences President

MYOV -  USA Stock  

USD 20.88  0.06  0.29%

  President
Mr. Jeffrey D. Nornhold is Senior Vice President, Pharmaceutical Operations Development of the Company. Mr. Nornhold previously served as Senior Vice President of Technical Operations for Impax Laboratories, where he was responsible for Impax manufacturing, supply chain, quality and technical operations. Prior to that, he served as Impax Senior Vice President, Global Quality Affairs, and was responsible for establishing a sustainable quality and compliance program. Prior to Impax, Mr. Nornhold served as Vice President, Quality Operations International for Watson Pharmaceuticals, Inc., and was responsible for exU.S. manufacturing sites for both dosage and active pharmaceutical ingredients. While atWatson, he also served as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites. Earlier in his career, he held numerous leadership positions in the pharmaceutical industry
Age: 52  President Since 2018  MBA    
44 20 7400 3351  http://myovant.com
Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.

Myovant Sciences Management Efficiency

Myovant Sciences has return on total asset (ROA) of (35.36) % which means that it has lost $35.36 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 20.67 %, meaning that it created $20.67 on every $100 dollars invested by stockholders. Myovant Sciences management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Equity is likely to climb to 1.09 in 2021, whereas Return on Average Assets are likely to drop (0.63)  in 2021. Myovant Sciences Total Assets are fairly stable at the moment as compared to the past year. Myovant Sciences reported Total Assets of 725.03 Million in 2020. Current Assets is likely to climb to about 760.3 M in 2021, whereas Return on Average Assets are likely to drop (0.63)  in 2021.
The company currently holds 369.7 M in liabilities with Debt to Equity (D/E) ratio of 138.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Myovant Sciences has a current ratio of 2.46, suggesting that it is liquid enough and is able to pay its financial obligations when due.
The market value of Myovant Sciences is measured differently than its book value, which is the value of Myovant that is recorded on the company's balance sheet. Investors also form their own opinion of Myovant Sciences' value that differs from its market value or its book value, called intrinsic value, which is Myovant Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myovant Sciences' market value can be influenced by many factors that don't directly affect Myovant Sciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myovant Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Myovant Sciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myovant Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Similar Executives

Found 4 records

PRESIDENT Since

Robert JanssenDynavax Technologies
2018
David JohnsonDynavax Technologies
2014
Ryan SpencerDynavax Technologies
2019
Michael OstrachDynavax Technologies
2016
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womens health and endocrine diseases. Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. Myovant Sciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 407 people. Myovant Sciences (MYOV) is traded on New York Stock Exchange in USA. It is located in 11-12 St. James’s Square and employs 407 people. Myovant Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Myovant Sciences Leadership Team

Elected by the shareholders, the Myovant Sciences' board of directors comprises two types of representatives: Myovant Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Myovant. The board's role is to monitor Myovant Sciences' management team and ensure that shareholders' interests are well served. Myovant Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Myovant Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Keith Manchester, Director
Frank Karbe, Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc.
Juan Ferreira, Chief Commercial Officer - Myovant Sciences, Inc
Marianne Romeo, Head, Global Transactions & Risk Management
Mark Altmeyer, Independent Director
Frank Torti, Director
Vivek Ramaswamy, Director
Jeffrey Nornhold, Senior Vice President Pharmaceutical Operations & Development
Kim Sablich, Chief Commercial Officer
Wayne DeVeydt, Independent Director
Matthew Lang, General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc.
Kathleen Sebelius, Lead Independent Director
Adele Gulfo, Director, Interim Chief Commercial Officer
Mark Guinan, Independent Director
Myrtle Potter, Chairman of the Board
David Marek, Principal Executive Officer, Director
Terrie Curran, Independent Director
Hiroshi Nomura, Director
Lynn Seely, Principal Executive Officer, Director

Myovant Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Myovant Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Myovant Sciences Investors Sentiment

The influence of Myovant Sciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Myovant. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - MYOV

Myovant Sciences Investor Sentiment

Most of Macroaxis users are now bullish on Myovant Sciences. What is your trading attitude regarding investing in Myovant Sciences? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Myovant Sciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Myovant Sciences information on this page should be used as a complementary analysis to other Myovant Sciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Myovant Stock analysis

When running Myovant Sciences price analysis, check to measure Myovant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Myovant Sciences is operating at the current time. Most of Myovant Sciences' value examination focuses on studying past and present price action to predict the probability of Myovant Sciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Myovant Sciences' price. Additionally, you may evaluate how the addition of Myovant Sciences to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
The market value of Myovant Sciences is measured differently than its book value, which is the value of Myovant that is recorded on the company's balance sheet. Investors also form their own opinion of Myovant Sciences' value that differs from its market value or its book value, called intrinsic value, which is Myovant Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myovant Sciences' market value can be influenced by many factors that don't directly affect Myovant Sciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myovant Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Myovant Sciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myovant Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.